Methods of reducing risk of cardiovascular disease
Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease, having a recurrent cardiovascular event or reducing the severity of a secondary cardiovascular event, wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.
1. A method of decreasing a patient's risk for developing coronary heart disease or having a recurrent cardiovascular event, comprising administering to the patient an effective amount of the compound:
or an ester, or a salt, or a hydrate thereof,
wherein the patient is on a stable dose of statin and requires additional lowering of LDL-C.
2. A method of preventing, delaying the onset of, or reducing the severity of a secondary cardiovascular event, comprising administering to a patient in need thereof, an effective amount of the compound:
or an ester, or a salt, or a hydrate thereof,
wherein the patient is on a stable dose of statin and requires additional lowering of LDL-C.
3. The method according to claim 1 , wherein the patient has an LDL-C level above treatment goal.
4. The method according to claim 3 , wherein the patient has coronary heart disease or a coronary heart risk equivalent, or has had a previous primary cardiovascular event, or a previous cerebral vascular event.
5. The method according to claim 4 , wherein the patient has one or more risk factors selected from the group consisting of smoking, hypertension, treatment with an antihypertensive medication, HDL cholesterol level less than 40 mg/dL, family history of premature coronary heart disease, male at least 45 years, and female at least 55 years.
6. The method according to claim 4 , wherein the patient has a 10-year risk for coronary heart disease of at least 10%.
7. The method according to claim 4 , wherein the patient's Framingham Risk Score is reduced by at least 1 point.
8. The method according to claim 4 , wherein the patient is diabetic.
9. The method according to claim 4 , wherein the patient has an HDL cholesterol level less than 40 mg/dL and a blood triglyceride levels at least 150 mg/dL.
10. The method according to claim 4 , wherein the patient is administered one or more additional cholesterol lowering drug independently selected from the group consisting of: a cholesterol absorption inhibitor, a bile acid sequestrant, a cholesteryl ester transfer protein inhibitor, a microsomal triglyceride transfer protein inhibitor, a PCSK9 inhibitor, a microRNA-33 inhibitor, a squalene synthase inhibitor and an apoB synthesis inhibitor.
11. The method according to claim 3 , wherein the compound is a calcium salt of gemcabene.
12. The method according to claim 3 , wherein the compound is the monocalcium salt of gemcabene.
13. The method according to claim 2 , wherein the patient has an LDL-C level above treatment goal.
14. The method according to claim 13 , wherein the patient has coronary heart disease or a coronary heart risk equivalent, or has had a previous primary cardiovascular event, or a previous cerebral vascular event.
15. The method according to 14 , wherein the patient has one or more risk factors selected from the group consisting of smoking, hypertension, treatment with an antihypertensive medication, HDL cholesterol level less than 40 mg/dL, family history of premature coronary heart disease, male at least 45 years, and female at least 55 years.
16. The method according to claim 14 , wherein the patient has a 10-year risk for coronary heart disease of at least 10%.
17. The method according to claim 14 , wherein the patient's Framingham Risk Score is reduced by at least 1 point.
18. The method according to claim 14 , wherein the patient is diabetic.
19. The method according to claim 14 , wherein the patient has an HDL cholesterol level less than 40 mg/dL and a blood triglyceride levels at least 150 mg/dL.
20. The method according to claim 14 , wherein the patient is administered one or more additional cholesterol lowering drug independently selected from the group consisting of: a cholesterol absorption inhibitor, a bile acid sequestrant, a cholesteryl ester transfer protein inhibitor, a microsomal triglyceride transfer protein inhibitor, a PCSK9 inhibitor, a microRNA-33 inhibitor, a squalene synthase inhibitor and an apoB synthesis inhibitor.
21. The method according to claim 13 , wherein the compound is a calcium salt of gemcabene.
22. The method according to claim 13 , wherein the compound is the monocalcium salt of gemcabene.
23. A method of decreasing a patient's Framingham Risk Score, comprising administering to a patient on a stable dose of a statin, an effective amount of the compound:
or the free acid, a salt, or a hydrate thereof,
wherein the patient's Framingham Risk Score is reduced by at least 1 point following the administration of the compound.